Clinical experience with U500 insulin: Risks and benefits

Endocrine Practice

Volumn 18, Issue 1, 2012, Pages 56-61

  Boldo, Angela ^a   Comi, Richard J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; SHORT ACTING INSULIN; U 500 INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; DRUG COST; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSURANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW;

ADULT; BODY WEIGHT; CLINICAL PROTOCOLS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84857579404     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11163.OR     Document Type: Article

References (14)

1. Binder C. Absorption of injected insulin. A clinical-phar-macological study. Acta Pharmacol Toxicol (Copenh). 1969;27(Suppl 2):1-84.
2. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
3. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15:71-79.
4. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67:1526-1535.
5. Berson SA, Yalow RS. Insulin antagonists, insulin anti-bodies and insulin resistance. Am J Med. 1958;25:155-159.
6. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med. 1991;325: 938-948.
7. Kahn CR, Rosenthal AS. Immunologic reactions to insu-lin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care. 1979;2:283-295.
8. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmaco-kinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33:281-283.
9. Khan M, Sarabu B. The pharmacokinetic and pharma-codynamic properties of regular U-500 insulin in healthy obese subjects [Abstract]. Diabetes. 2009;58:2333P.
10. The effect of intensive treatment of diabetes on the devel-opment and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993;329:977-986.
11. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259-264.
12. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lis-pro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20-25.
13. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240-1244.
14. Nayyar V, Lawrence I, Kong M. Long-term follow-up of patients on U-500 human actrapid [Abstract]. Diabetologia. 2007;50(Suppl 1):S395.